Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report

Minoru Kojima, Daisuke Ogiya, Akifumi Ichiki, Ryujiro Hara, Jun Amaki, Hidetsugu Kawai, Hiroki Numata, Ai Sato, Mitsuki Miyamoto, Rikio Suzuki, Shinichiro Machida, Hiromichi Matsushita, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

A 40-year-old male developed refractory acute promyelocytic leukemia (APL) after various treatments including all-trans retinoic acid, tamibarotene, arsenic trioxide (As2O3), conventional chemotherapy, and autologous peripheral blood stem cell transplantation. We attempted to use both tamibarotene and As2O3 as a combination therapy, and he achieved molecular complete remission. Grade 2 prolongation of the QTc interval on the electrocardiogram was observed during the therapy. The combination therapy of As2O3 and tamibarotene may be effective and tolerable for treating refractory APL cases who have no treatment options, even when they have previously been treated with tamibarotene and As2O3 as a single agent.

Original languageEnglish
Pages (from-to)11-13
Number of pages3
JournalLeukemia Research Reports
Volume5
DOIs
Publication statusPublished - 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report'. Together they form a unique fingerprint.

Cite this